依贝沙坦联合羟苯磺酸钙治疗30例糖尿病肾病效果分析
摘要目的:观察依贝沙坦联合羟苯磺酸钙治疗糖尿病肾病的临床疗效。方法:将60例糖尿病肾病患者随机分为观察组与对照组各30例。观察组患者给予依贝沙坦口服150 mg/d,联合羟苯磺酸钙分散片口服500 mg/次、3次/d进行治疗;对照组患者单纯给予依贝沙坦口服150 mg/d,两组疗程均为3个月,两组患者在疗程开始之前与疗程结束之日检测患者的血压和肾功能指标(尿b-微球蛋白、血清肌酐、尿素氮、24 h尿蛋白)等,并观察记录两组患者不良反应情况。结果:用药后,两组患者血压和肾功能指标均明显改善(P中国论文网/6/view-
关键词糖尿病肾病联合用药羟苯磺酸钙依贝沙坦
中图分类号: 文献标识码:B 文章编号:1006-1533(2017)05-0015-03
Analysis of the effectiveness of bined with calcium dobesilate in the treatment of 30 cases of patients with diabetic nephropathy
ZHOU Ruiqin*, CHEN Yan
(Division One of Internal Medicine, the Third People’s Hospital of Luohe City, Luohe 462000, China)
ABSTRACT Objective: To explore the clinical effect of bined with calcium dobesilate in the treatment of diabetic nephropathy. Methods: Sixty cases of patients with diabetic nephropathy were randomly divided into an observation group and a control group with 30 cases each. The observation group was treated with 150 mg of irbesartan bined with 500 mg of calcium dobesilate dispersible tablets, 3 times a day while the control group was treated only with irbesartan, and the treatment was lasted for three months. The blood pressure, renal function indexes (urinary b-mini-globulin, serum creatinine, urea nitrogen and 24-hour urinary protein) plications pared. Results: After treatment, the blood pressure and renal function indexes were reduced in the two groups but more obviously in the observation group ()。 入选标准
①所有患者均需符合世界卫生组织(WHO)2型糖尿病的诊断标准[3];②所有患者均需符合丹麦学者Mogensen的糖尿病肾病诊断与分期标准[4],尿白蛋白排泄率>30 mg/24 h;③患者收缩压(systolic blood pressure, SBP)>140 mmHg,舒张压(diastolic blood pressure, DBP)>90 mmHg;④年龄在18~75岁之间。
排除标准
①排除伴有原发肾脏疾病和(或)严重肾功能损害者;②排除由糖尿病之外的其他疾病导致的肾功能损害患者;③排除妊娠或哺乳期妇女;④排除严重的心、脑、肝、肺部疾病患者;⑤排除精神疾病患者。
治疗方法
两组患者均给予个体化的降糖药物控制血糖,采取低盐、低糖、低脂饮食。在此基础之上,观察组给予依贝沙坦(国药准字J20130049;商品名:安博维;杭州赛诺菲安万特民生制药有限公司)口服150 mg/d,联合羟苯磺酸钙分散片(国药准字H20080288;商品名:朗仕;江苏万高药业有限公司)口服500 mg/次、3次/d进行治疗;对对照组单纯给予依贝沙坦口服150 mg/d。两组疗程均为3个月。
观察指标
分别在
博士买驴 中国成语故事连环画 成语故事 教学课件(ppt) 来自淘豆网m.daumloan.com转载请标明出处.